Matthew Wall
Neuroscientist
Data updated
Research Footprint
Matthew Wall appears in 17 tracked papers (2013–2026), most studied alongside Psilocybin, MDMA and LSD, across Neuroimaging & Brain Measures, Depressive Disorders and Healthy Volunteers.
Most-cited paper: Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms (585 citations).
Frequent co-authors: David Nutt, Robin Carhart-Harris and Leor Roseman.
Publication Landscape
How the 17 papers Blossom tracks for Matthew Wall line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Matthew Wall's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 17 of 17 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Matthew Wall publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Matthew Wall publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Matthew Wall is a neuroimaging scientist based at Imperial College London who specialises in functional MRI studies of psychoactive compounds and their effects on human brain function. He has collaborated with leading psychedelic research groups and clinical teams to image acute and short-term brain changes after administration of psilocybin, LSD and MDMA, and has acted as principal imaging scientist on early fMRI investigations of psilocybin in treatment-resistant depression. His methodological work spans task-evoked and resting-state paradigms and includes studies linking musical and emotional processing to drug-induced changes in brain activity.
Wall's contributions include empirical studies of LSD- and MDMA-related modulation of striato‑cortical connectivity, investigations of music‑evoked brain responses under LSD, analyses of first‑use psilocybin brain changes, and naturalistic work on MDMA/ecstasy and social behaviour. He is a co-author of recent reviews charting the role of neuroimaging in psychedelic drug development and has helped to integrate network‑level and affective neuroscience perspectives into translational research on psychedelic-assisted therapies.
Key Impact
Noted for advancing neuroimaging characterisation of how classic and entactogenic psychedelics (psilocybin, LSD, MDMA) alter large-scale brain networks and emotional processing, informing clinical development.
Collaboration Network
35 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Matthew Wall's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Matthew Wall is associated with.